RxDoctor Payments Data

Amy Bales, MD

Cardiovascular Disease · Hobart, INNPI 1255313540

Payments from drug & device makers

$6,689in general payments, 2019–2025

Across 387 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$901
  • Boehringer Ingelheim$542
  • AstraZeneca$513
  • Amgen$440
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$389
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$6,58598%
  • Education$290%
  • Gifts$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,689 in reported general payments places this provider in the 65th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$267,080
Medicare patients
721
Services billed
2,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis25$558,886
EliquisApixaban289$326,396
EntrestoSacubitril/Valsartan191$210,397
XareltoRivaroxaban118$137,659
JardianceEmpagliflozin65$81,600
FarxigaDapagliflozin Propanediol69$78,143
Repatha SureclickEvolocumab60$57,078
BrilintaTicagrelor58$50,777
Praluent PenAlirocumab31$19,574
DiovanValsartan11$15,898
VascepaIcosapent Ethyl18$15,769
Breo ElliptaFluticasone/Vilanterol15$8,162
Metoprolol Succinate672$8,139
Ezetimibe152$4,543
Rosuvastatin Calcium371$3,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$359$885,283314 claims
NovartisEntresto, Diovan$1,307$226,295202 claims
Johnson & JohnsonXarelto$901$137,659118 claims
AstraZenecaFarxiga, Brilinta$513$128,920127 claims
Boehringer IngelheimJardiance$542$81,60065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Hobart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →